Log in to save to my catalogue

Migraine, interferon β1a and siponimod immunomodulator therapies

Migraine, interferon β1a and siponimod immunomodulator therapies

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3dd52525a8be4472a568e48a0ecdf87e

Migraine, interferon β1a and siponimod immunomodulator therapies

About this item

Full title

Migraine, interferon β1a and siponimod immunomodulator therapies

Publisher

England: BioMed Central

Journal title

BMC anesthesiology, 2022-04, Vol.22 (1), p.95-4, Article 95

Language

English

Formats

Publication information

Publisher

England: BioMed Central

More information

Scope and Contents

Contents

Autoimmunity seems to play a great role in the pathogenesis of migraine headache pain. There is far more evidence that interferon can exacerbate migraines. We report a case where remission of severe comorbid migraine attacks happened with the start of interferon β1a (Merck, Netherlands) immunomodulation therapy. Therapy for multiple sclerosis was d...

Alternative Titles

Full title

Migraine, interferon β1a and siponimod immunomodulator therapies

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_3dd52525a8be4472a568e48a0ecdf87e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3dd52525a8be4472a568e48a0ecdf87e

Other Identifiers

ISSN

1471-2253

E-ISSN

1471-2253

DOI

10.1186/s12871-022-01639-z

How to access this item